Previous 10 | Next 10 |
– New preclinical data support the ongoing preclinical development of STK-002 for the treatment of autosomal dominant optic atrophy (ADOA) – – ADOA is the most common inherited optic nerve disorder – Stoke Therapeutics, Inc. (Nasdaq: S...
Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced that management will present at the 21st Annual Needham Virtual Healthcare Co...
Gainers: Adaptive Biotechnologies Corporation (ADPT) +5%. Angi (ANGI) +5%. Sangamo Therapeutics (SGMO) +5%. Nikola Corporation (NKLA) +5%. Core Scientific (CORZ) +5%. Losers: ON Semiconductor Corporation (ON) -13%. Apellis Pharmaceuticals (APLS) -7%. Redbox Entertain...
Stoke Therapeutics press release (NASDAQ:STOK): Q4 GAAP EPS of -$0.66 misses by $0.04. As of December 31, 2021, Company had $220.4 million in cash, cash equivalents, marketable securities, and restricted cash For further details see: Stoke Therapeutics GAAP EPS of -$0.66 misses by $0.04...
– Enrollment and dosing ongoing in the Phase 1/2a MONARCH and ADMIRAL studies of STK-001 in children and adolescents with Dravet syndrome – – Company remains on track to provide additional clinical data in 2H 2022 from patients treated with multiple ascend...
Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced that management will participate on the Orphan Neuro Panel at the Cowen 42nd ...
H.C. Wainwright has upgraded Acadia Pharmaceuticals (NASDAQ:ACAD) to buy from neutral on the potential of trofinetide to take market share for Rett syndrome. The firm has doubled its price target of $36 (34% upside based on Wednesday's close). The target assumes estimated revenue of $1.8B fro...
– Establishes co-development and co-commercialization agreement for Stoke’s SYNGAP1 preclinical program – Acadia receives exclusive worldwide licenses for two additional preclinical programs: Rett syndrome (MECP2) and undisclosed neurodevelopmental target ...
Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced that management will present at the 40th Annual J.P. Morgan Healthcare Confer...
Stoke Therapeutics (STOK -2.1%) disclosed interim data from its Phase 1/2a MONARCH study for Antisense Oligonucleotide, STK-001 in children and adolescents with Dravet Syndrome, a hereditary form of epilepsy leading to seizures. In the trial involving subjects aged 2 to 18 years, STK-001 was ...
News, Short Squeeze, Breakout and More Instantly...
Stoke Therapeutics Inc. Company Name:
STOK Stock Symbol:
NYSE Market:
Stoke Therapeutics Inc. Website:
2024-06-16 20:36:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced that management will present at the following upcoming investor conferences: Goldma...
2024-05-16 08:32:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...